Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
ProMIS Neurosciences Inc
PMN
Healthcare
Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational...
discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:PMN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(93)
•••
Gbathat
X
View Profile
View Bullboard History
Comment by
Gbathat
on Jan 12, 2025 11:24pm
RE:Leede Jones
Abbvie acquired Aliada for $1.4B
(198)
•••
goldtech
X
View Profile
View Bullboard History
Post by
goldtech
on Jan 12, 2025 3:32pm
Leede Jones
PMN:TSX; PMN:NCM) with a price target of US$9.50. The report follows ProMIS's presentation of interim Phase I data for PMN310, its Alzheimer's disease (AD) candidate, at the Clinical
...more
(11)
•••
Blueknowser1
X
View Profile
View Bullboard History
Comment by
Blueknowser1
on Jan 12, 2025 2:51pm
RE:RE:RE:Phase 1b
All good information- thanks!
(93)
•••
Gbathat
X
View Profile
View Bullboard History
Comment by
Gbathat
on Jan 10, 2025 12:32pm
RE:RE:RE:Phase 1b
Seems great. Based on their past behavior, I'd suspect a partnership approach. Unless they are just exhausted and ready to cash out themselves. But I feel like the technical dev
...more
(61)
•••
bball67
X
View Profile
View Bullboard History
Comment by
bball67
on Jan 10, 2025 10:49am
RE:RE:Phase 1b
Promis has committed to releasing biomarker results after six months of treatment of PMN310 by press release and a SEC filing. There are about 8 or 9 biomarkers. After this, warrant holders from the
...more
(11)
•••
Blueknowser1
X
View Profile
View Bullboard History
Comment by
Blueknowser1
on Jan 10, 2025 10:42am
RE:RE:Phase 1b
CEO Warma mentions while speaking at the HealthCONx Conference, that there'd potentially be updates sooner, but without listening to that webcast again, I'm not sure.
(106)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Jan 10, 2025 10:38am
RE:RE:Phase 1b
In October, they reported the following on the Phase 1A: "PMN310 was generally well-tolerated in all five single-ascending dose cohorts (2.5, 5, 10, 20 and 40 mg/kg) of the Phase 1a clinical
...more
(21)
•••
BottomBroker
X
View Profile
View Bullboard History
Comment by
BottomBroker
on Jan 10, 2025 9:53am
RE:Phase 1b
"We are excited about the opportunity to deliver real innovation to patients and look forward to sharing updates as we progress, with certain interim data anticipated in the first half of 2026
...more
(21)
•••
BottomBroker
X
View Profile
View Bullboard History
Comment by
BottomBroker
on Jan 10, 2025 9:47am
RE:RE:PMN faces delisting from NASDAQ (again)
Ah, okay. That makes sense now. Thanks for the clarification, bball.
(61)
•••
bball67
X
View Profile
View Bullboard History
Comment by
bball67
on Jan 10, 2025 8:40am
RE:PMN faces delisting from NASDAQ (again)
Based on the previous delisting notice last July? The market cap requirement was $35M. The shares outstanding today are a little short of 35M shares, so the required share price is approximately $1
...more
(11)
•••
Blueknowser1
X
View Profile
View Bullboard History
Post by
Blueknowser1
on Jan 10, 2025 8:14am
Phase 1b
Can't wait to hear some of the positive results. Love the name: Mr. Warma added “the trial name, PRECISE-AD, was chosen to reflect our focus on Personalized, Robust, and
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 10, 2025 7:00am
New Press Release - ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer's Disease
Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced outcomes for patients CAMBRIDGE, Massachusetts, Jan. 10, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on...
read article.
(21)
•••
BottomBroker
X
View Profile
View Bullboard History
Post by
BottomBroker
on Jan 09, 2025 4:56pm
PMN faces delisting from NASDAQ (again)
https://www.investing.com/news/sec-filings/promis-neurosciences-faces-nasdaq-delisting-over-share-price-93CH-3804581 They've got until July to get it together. But since when is the threshold
...more
(106)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Jan 09, 2025 2:45pm
RE:RE:RE:RE:RE:RE:ARIA-E
Yes. BB, I fully agree with your explanation. The binding of AB plaque is more commonly associated with causing ARIA-E. Since the trial involves healthy volunteers, the likelihood of developing ARIA
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Eminent's First Drill Hole Hits Significant Gold-Arsenic in Getchell Trend Analogue and Second Hole Drilling Commences
U.S. DOD Logistics Agency Highlights V.GPH Project to Develop Eco-Friendly Graphite-Based Fire-Fighting Material
Have you held units of a TD mutual fund, other than through a discount broker? Learn more.
Alphamin Announces Record Fy2024 & Q4 2024 Tin Production Fy2025 Production Guidance Exploration Success
BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market projected to grow to USD$48,000,000,000 by 2030*